Cargando…
Engineering designer beta cells with a CRISPR-Cas9 conjugation platform
Genetically fusing protein domains to Cas9 has yielded several transformative technologies; however, the genetic modifications are limited to natural polypeptide chains at the Cas9 termini, which excludes a diverse array of molecules useful for gene editing. Here, we report chemical modifications th...
Autores principales: | Lim, Donghyun, Sreekanth, Vedagopuram, Cox, Kurt J., Law, Benjamin K., Wagner, Bridget K., Karp, Jeffrey M., Choudhary, Amit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426819/ https://www.ncbi.nlm.nih.gov/pubmed/32792475 http://dx.doi.org/10.1038/s41467-020-17725-0 |
Ejemplares similares
-
Chemogenetic System Demonstrates That Cas9 Longevity Impacts Genome Editing Outcomes
por: Sreekanth, Vedagopuram, et al.
Publicado: (2020) -
Bioorthogonal CRISPR/Cas9‐Drug Conjugate: A Combinatorial Nanomedicine Platform
por: Beha, Marcel Janis, et al.
Publicado: (2023) -
A 3D culture platform enables development of zinc-binding prodrugs for targeted proliferation of β cells
por: Yang, Kisuk, et al.
Publicado: (2020) -
Molecular engineering of antibodies for site-specific covalent conjugation using CRISPR/Cas9
por: Khoshnejad, Makan, et al.
Publicado: (2018) -
A molecular glue approach to control the half-life of CRISPR-based technologies
por: Sreekanth, Vedagopuram, et al.
Publicado: (2023)